Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome
about
Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndromeHuman menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cyclesGonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproductive treatmentHuman menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cyclesThe management of infertility associated with polycystic ovary syndromeMixed protocols: multiple ratios of FSH and LH bioactivity using highly purified, human-derived FSH (BRAVELLE) and highly purified hMG (MENOPUR) are unaltered by mixing together in the same syringe.Effectiveness of GnRH antagonist in the management of subfertile couples undergoing controlled ovarian stimulation and intrauterine insemination: a meta-analysisComparison of highly purified FSH (metrodin-high purity) with pergonal for IVF superovulationEffects of hyperandrogenemia and increased adiposity on reproductive and metabolic parameters in young adult female monkeysThe Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndromeEffect of gonadotropin-releasing hormone antagonists on intrauterine insemination cycles in women with polycystic ovary syndrome: a meta-analysis.Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome.Anovulation and ovulation induction.Polycystic ovarian syndrome: diagnosis and management.The Distribution of Stroma and Antral Follicles Differs between Insulin-Resistance and Hyperandrogenism-Related Polycystic Ovarian Syndrome.Aging and reproductive potential in women.Statins in the treatment of polycystic ovary syndrome.Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles.Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome.Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndromeComparative evaluation of pregnancy outcome in gonadotrophin-clomiphene combination vs clomiphene alone in polycystic ovarian syndrome and unexplained infertility-A prospective clinical trial.Clomiphene citrate--end of an era? A mini-review.Metformin reduces abortion in pregnant women with polycystic ovary syndrome.Luteinizing hormone and its dilemma in ovulation induction.Recurrent spontaneous abortion and polycystic ovarian disease: comparison of two regimens to induce ovulation.Recurrent early miscarriage and polycystic ovaries.One hundred pregnancies after treatment with pulsatile luteinising hormone releasing hormone to induce ovulationAdverse pregnancy outcomes with assisted reproductive technology in non-obese women with polycystic ovary syndrome: a case-control studyIn vitro fertilization treatment in patients with polycystic ovaries.The significance of high follicular-phase luteinizing hormone levels in the treatment of women with polycystic ovarian syndrome by in vitro fertilization.Oocyte quality in polycystic ovaries revisited: identification of a particular subgroup of women.Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol.A randomized prospective cross-over study of highly purified follicle-stimulating hormone and human menopausal gonadotrophin for ovarian hyperstimulation in women aged 37-41 years.Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: A randomized controlled trialDoes suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial.Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome?Endocrine dysfunction and recurrent spontaneous abortion: An overview.Therapeutic options in the polycystic ovary syndrome.The influence of the environment and other exogenous agents on spontaneous abortion risk.Current trends in the treatment of polycystic ovary syndrome with desire for children.
P2860
Q24188044-C1477AFC-CE0B-4B9D-A0C5-70D76DE543A2Q24234251-ACB2B692-1C26-4DB0-B5EA-1DC2E1CA3E44Q24240778-E34A2298-7EDA-4D6B-9C2F-8582C4637517Q24250231-4E6A082B-DF7E-40A1-879D-317E063153C2Q24798425-0D59E52E-2108-416E-B14C-D8977C78FE87Q24814392-221C60D0-6FD6-4008-93ED-293A07B5E908Q27003082-796B03AE-E298-43EE-BD5C-EF022013C0DDQ28265421-B33AABA2-EFC7-422D-A5A1-AAF1A964D5A1Q30389395-EC0E3F96-1172-4F2D-8AD9-4C97ABC5E59EQ30419504-ECF48BBA-7460-4F8B-AD90-387248875346Q31145069-06273CD3-8A1F-4009-A525-252B9F28D619Q33230782-B7DE667C-B1CB-41B4-A804-1E9626F13CE7Q33598521-0388D192-11BF-4563-99FC-DC46B86C86BEQ33723471-F3B327B3-2764-4646-AF6F-ADF47AE8B6A8Q33740749-0276C366-D2DD-4F3D-B259-5CB38F064CA2Q33754806-132A07B1-6EBE-49DA-A749-D3CF3F9493B1Q33789151-A9491B4C-F6F2-4E0B-9306-53F802920A87Q33908471-E2822AB8-BB63-460E-BEC4-CB717C49663DQ33921751-D9AC18F6-F6F5-4DA1-87E2-5D17BB831CE5Q34129292-1A8F045D-D202-4A7C-8D33-DCE030293496Q34268679-4FD21B0E-3687-43D3-B2C7-50967DB7FDDEQ34557430-400E27F5-7651-492F-B32C-9734E30E8E37Q34590034-7D53D6A2-31DC-4EED-BCC4-3A7EC03E04A0Q35104484-21310761-6F28-4755-BCC2-B94BB22626CDQ35167856-41A93854-5A81-4F2D-8CBA-D2C30EFADA1DQ35704784-34F84904-2817-4C9B-B23D-02E468044488Q35709865-84F960DC-6535-4952-A81F-2FA0E6942F01Q35767806-C58F5412-3F0B-4ED6-A878-6CB4171A9DD4Q36267439-01636401-A51E-461A-BA64-914786890B14Q36267453-5A221C27-1BFC-4814-B9BD-9E371CC8DE5AQ36267478-96DA6CA1-3F9C-4EC5-A39E-50B7FF49D6F6Q36268229-E71001F9-8C27-43B9-9D00-04B39333E4E8Q36269264-21EA1810-D604-4BA9-A586-8E6344F2B61DQ36406468-CADDDAE2-E58C-4D1E-A043-E38EEE23A4BDQ36598852-B4C336BA-AFDC-4E72-9D0B-2BB17BAFC286Q36673559-19EED22A-63AD-4CC6-A0EC-EF3B9E5203A5Q36794012-E02DD75C-F0C1-46AD-8359-2DB29AD9B9DBQ36799800-6430FD5D-8ACD-4E1A-B05B-AB34D4F76AE9Q37119897-91A71F45-1AE5-4FA6-901B-C710FE30F8CDQ37230319-DA6DE013-2C4A-4719-8E0F-30566548BAE7
P2860
Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Influence of serum luteinising ...... s in polycystic ovary syndrome
@ast
Influence of serum luteinising ...... s in polycystic ovary syndrome
@en
type
label
Influence of serum luteinising ...... s in polycystic ovary syndrome
@ast
Influence of serum luteinising ...... s in polycystic ovary syndrome
@en
prefLabel
Influence of serum luteinising ...... s in polycystic ovary syndrome
@ast
Influence of serum luteinising ...... s in polycystic ovary syndrome
@en
P2093
P2860
P1433
P1476
Influence of serum luteinising ...... s in polycystic ovary syndrome
@en
P2093
P2860
P304
P356
10.1136/BMJ.297.6655.1024
P407
P577
1988-10-01T00:00:00Z